Validation of Ella Platform for Serum Nfl And GFAP Measures In Multiple Sclerosis Patients
NCT ID: NCT05352971
Last Updated: 2023-10-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
664 participants
OBSERVATIONAL
2022-09-15
2023-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Serum Neurofilament-light Chain and GFAP Levels in Patients From the OFSEP Cohort at Different Landmarks of Multiple Sclerosis
NCT03981003
Serum Neurofilament Light in Multiple Sclerosis
NCT06282081
Serum Neurofilaments and GFAP in Atypical Multiple Sclerosis
NCT04201470
Multimodal Exploration of Patients With Multiple Sclerosis for an Early Detection of Subtle Progression
NCT05941975
Assessment of NfL and GFAP Levels, Atrophy of the Macula GCC by OCT and Whole Brain Atrophy by MRI to Predict Evolution of Neurological Disability in MS Patients
NCT04860947
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with multiple sclerosis
Biomarker quantification
Patient blood samples will be tested on 2 different platforms
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Biomarker quantification
Patient blood samples will be tested on 2 different platforms
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least one native (no thaw-freeze cycle) serum sample in local or in centralized Biological Resource Center
Exclusion Criteria
* No OFSEP minimal sheet at baseline
15 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire de Nīmes
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eric Thouvenot
Role: PRINCIPAL_INVESTIGATOR
CHU de Nimes
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Clermont-Ferrand
Clermont-Ferrand, , France
Hôpital Henri Mondor
Créteil, , France
CHRU Lille
Lille, , France
Hospices Civils de Lyon
Lyon, , France
CHU Gui de Chauliac
Montpellier, , France
CHU de Nantes,
Nantes, , France
Centre Hospitalier Universitaire Pasteur 2
Nice, , France
CHU de Nîmes
Nîmes, , France
Hôpital Pitié-Salpêtrière
Paris, , France
CHU de Strasbourg
Strasbourg, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CIVI/2021/ET-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.